nodes	percent_of_prediction	percent_of_DWPC	metapath
Amsacrine—ABCB1—colon cancer	0.652	1	CbGaD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—PTPN12—colon cancer	0.00777	0.0898	CbGpPWpGaD
Amsacrine—NCOA3—Topotecan—Irinotecan—colon cancer	0.00739	0.746	CbGdCrCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—RAD54L—colon cancer	0.00623	0.072	CbGpPWpGaD
Amsacrine—NCOA3—Validated nuclear estrogen receptor alpha network—AXIN2—colon cancer	0.00539	0.0623	CbGpPWpGaD
Amsacrine—NCOA3—smooth muscle tissue—colon cancer	0.00391	0.101	CbGeAlD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—ODC1—colon cancer	0.00377	0.0436	CbGpPWpGaD
Amsacrine—NCOA3—renal system—colon cancer	0.00376	0.0974	CbGeAlD
Amsacrine—NCOA3—lymphoid tissue—colon cancer	0.00312	0.0809	CbGeAlD
Amsacrine—NCOA3—digestive system—colon cancer	0.00308	0.0799	CbGeAlD
Amsacrine—NCOA3—bone marrow—colon cancer	0.00284	0.0736	CbGeAlD
Amsacrine—NCOA3—vagina—colon cancer	0.00272	0.0705	CbGeAlD
Amsacrine—NCOA3—liver—colon cancer	0.0023	0.0595	CbGeAlD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—MSH6—colon cancer	0.00206	0.0237	CbGpPWpGaD
Amsacrine—NCOA3—lymph node—colon cancer	0.00176	0.0456	CbGeAlD
Amsacrine—TOP2A—bone marrow—colon cancer	0.00167	0.0432	CbGeAlD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—MSH2—colon cancer	0.00167	0.0193	CbGpPWpGaD
Amsacrine—NCOA3—Retinoic acid receptors-mediated signaling—EP300—colon cancer	0.00165	0.0191	CbGpPWpGaD
Amsacrine—TOP2A—vagina—colon cancer	0.0016	0.0414	CbGeAlD
Amsacrine—CYP2D6—Codeine and Morphine Metabolism—ABCB1—colon cancer	0.00142	0.0164	CbGpPWpGaD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—MSH6—colon cancer	0.0014	0.0162	CbGpPWpGaD
Amsacrine—KCNH2—renal system—colon cancer	0.00124	0.032	CbGeAlD
Amsacrine—NCOA3—FOXA1 transcription factor network—EP300—colon cancer	0.00122	0.0141	CbGpPWpGaD
Amsacrine—ABCB1—blood vessel—colon cancer	0.0012	0.0311	CbGeAlD
Amsacrine—NCOA3—Transcriptional regulation of white adipocyte differentiation—PPARG—colon cancer	0.00119	0.0137	CbGpPWpGaD
Amsacrine—TOP2A—Gastric Cancer Network 1—APC—colon cancer	0.00118	0.0136	CbGpPWpGaD
Amsacrine—TOP2A—lymph node—colon cancer	0.00103	0.0268	CbGeAlD
Amsacrine—TOP2A—Topotecan—Irinotecan—colon cancer	0.00101	0.103	CbGdCrCtD
Amsacrine—Blood creatinine increased—Irinotecan—colon cancer	0.00101	0.00476	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—TOP1—colon cancer	0.00101	0.0117	CbGpPWpGaD
Amsacrine—NCOA3—Retinoic acid receptors-mediated signaling—AKT1—colon cancer	0.001	0.0115	CbGpPWpGaD
Amsacrine—Aspartate aminotransferase increased—Vincristine—colon cancer	0.000998	0.0047	CcSEcCtD
Amsacrine—Phosphatase alkaline increased—Capecitabine—colon cancer	0.000996	0.00468	CcSEcCtD
Amsacrine—CYP2D6—Metapathway biotransformation—CHST4—colon cancer	0.000994	0.0115	CbGpPWpGaD
Amsacrine—Injection site reaction—Capecitabine—colon cancer	0.00099	0.00466	CcSEcCtD
Amsacrine—NCOA3—Validated nuclear estrogen receptor alpha network—CCND1—colon cancer	0.00098	0.0113	CbGpPWpGaD
Amsacrine—Aspartate aminotransferase increased—Irinotecan—colon cancer	0.000972	0.00458	CcSEcCtD
Amsacrine—TOP2A—Circadian rythm related genes—TOP1—colon cancer	0.000971	0.0112	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—CA7—colon cancer	0.00096	0.0111	CbGpPWpGaD
Amsacrine—Hepatotoxicity—Methotrexate—colon cancer	0.00096	0.00452	CcSEcCtD
Amsacrine—Necrosis—Methotrexate—colon cancer	0.000944	0.00444	CcSEcCtD
Amsacrine—Gingivitis—Methotrexate—colon cancer	0.000944	0.00444	CcSEcCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—BAX—colon cancer	0.000944	0.0109	CbGpPWpGaD
Amsacrine—KCNH2—bone marrow—colon cancer	0.000934	0.0242	CbGeAlD
Amsacrine—Pancytopenia—Vincristine—colon cancer	0.00091	0.00428	CcSEcCtD
Amsacrine—NCOA3—Validated nuclear estrogen receptor alpha network—EP300—colon cancer	0.000902	0.0104	CbGpPWpGaD
Amsacrine—KCNH2—vagina—colon cancer	0.000895	0.0232	CbGeAlD
Amsacrine—NCOA3—PPARA activates gene expression—PPARG—colon cancer	0.000894	0.0103	CbGpPWpGaD
Amsacrine—Dysphagia—Fluorouracil—colon cancer	0.000894	0.00421	CcSEcCtD
Amsacrine—NCOA3—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—colon cancer	0.000875	0.0101	CbGpPWpGaD
Amsacrine—Weight decreased—Vincristine—colon cancer	0.000867	0.00408	CcSEcCtD
Amsacrine—Sepsis—Capecitabine—colon cancer	0.000864	0.00407	CcSEcCtD
Amsacrine—Extravasation—Methotrexate—colon cancer	0.00085	0.004	CcSEcCtD
Amsacrine—Pancytopenia—Fluorouracil—colon cancer	0.000849	0.00399	CcSEcCtD
Amsacrine—Weight decreased—Irinotecan—colon cancer	0.000844	0.00397	CcSEcCtD
Amsacrine—Proteinuria—Methotrexate—colon cancer	0.000844	0.00397	CcSEcCtD
Amsacrine—Phlebitis—Capecitabine—colon cancer	0.000839	0.00395	CcSEcCtD
Amsacrine—Stomatitis—Vincristine—colon cancer	0.000833	0.00392	CcSEcCtD
Amsacrine—Protein urine present—Methotrexate—colon cancer	0.000832	0.00391	CcSEcCtD
Amsacrine—Blood alkaline phosphatase increased—Capecitabine—colon cancer	0.000831	0.00391	CcSEcCtD
Amsacrine—Renal failure—Irinotecan—colon cancer	0.000818	0.00385	CcSEcCtD
Amsacrine—Stomatitis—Irinotecan—colon cancer	0.000811	0.00382	CcSEcCtD
Amsacrine—Jaundice—Irinotecan—colon cancer	0.000811	0.00382	CcSEcCtD
Amsacrine—Vascular purpura—Capecitabine—colon cancer	0.000808	0.0038	CcSEcCtD
Amsacrine—Hepatic failure—Capecitabine—colon cancer	0.000804	0.00378	CcSEcCtD
Amsacrine—Hyperuricaemia—Methotrexate—colon cancer	0.000799	0.00376	CcSEcCtD
Amsacrine—Infestation NOS—Fluorouracil—colon cancer	0.000797	0.00375	CcSEcCtD
Amsacrine—Infestation—Fluorouracil—colon cancer	0.000797	0.00375	CcSEcCtD
Amsacrine—NCOA3—Validated nuclear estrogen receptor alpha network—MYC—colon cancer	0.000786	0.00908	CbGpPWpGaD
Amsacrine—NCOA3—Transcriptional regulation of white adipocyte differentiation—EP300—colon cancer	0.000778	0.00899	CbGpPWpGaD
Amsacrine—Stomatitis—Fluorouracil—colon cancer	0.000777	0.00366	CcSEcCtD
Amsacrine—Inflammation—Methotrexate—colon cancer	0.000764	0.0036	CcSEcCtD
Amsacrine—Hypoaesthesia—Vincristine—colon cancer	0.000763	0.00359	CcSEcCtD
Amsacrine—Atrial fibrillation—Capecitabine—colon cancer	0.000763	0.00359	CcSEcCtD
Amsacrine—Bradycardia—Irinotecan—colon cancer	0.000761	0.00358	CcSEcCtD
Amsacrine—TOP2A—Gastric Cancer Network 2—CTNNB1—colon cancer	0.00076	0.00878	CbGpPWpGaD
Amsacrine—Urinary tract disorder—Vincristine—colon cancer	0.000758	0.00356	CcSEcCtD
Amsacrine—Blood uric acid increased—Methotrexate—colon cancer	0.000755	0.00355	CcSEcCtD
Amsacrine—Connective tissue disorder—Vincristine—colon cancer	0.000754	0.00355	CcSEcCtD
Amsacrine—CYP2D6—renal system—colon cancer	0.000754	0.0195	CbGeAlD
Amsacrine—NCOA3—Androgen receptor signaling pathway—CCND1—colon cancer	0.000753	0.0087	CbGpPWpGaD
Amsacrine—Urethral disorder—Vincristine—colon cancer	0.000752	0.00354	CcSEcCtD
Amsacrine—Haemoglobin—Irinotecan—colon cancer	0.000751	0.00353	CcSEcCtD
Amsacrine—Purpura—Capecitabine—colon cancer	0.00075	0.00353	CcSEcCtD
Amsacrine—Haemorrhage—Irinotecan—colon cancer	0.000747	0.00351	CcSEcCtD
Amsacrine—NCOA3—Androgen receptor signaling pathway—CTNNB1—colon cancer	0.000746	0.00861	CbGpPWpGaD
Amsacrine—Agranulocytosis—Fluorouracil—colon cancer	0.000744	0.0035	CcSEcCtD
Amsacrine—Lethargy—Capecitabine—colon cancer	0.000738	0.00347	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—DCC—colon cancer	0.000736	0.0085	CbGpPWpGaD
Amsacrine—Connective tissue disorder—Irinotecan—colon cancer	0.000734	0.00345	CcSEcCtD
Amsacrine—NCOA3—Androgen receptor signaling pathway—CDKN1A—colon cancer	0.000728	0.00842	CbGpPWpGaD
Amsacrine—TOP2A—Vindesine—Vincristine—colon cancer	0.000725	0.0733	CbGdCrCtD
Amsacrine—Haemoglobin—Fluorouracil—colon cancer	0.000719	0.00338	CcSEcCtD
Amsacrine—ABCB1—embryo—colon cancer	0.000716	0.0186	CbGeAlD
Amsacrine—Haemorrhage—Fluorouracil—colon cancer	0.000715	0.00337	CcSEcCtD
Amsacrine—Cardiac disorder—Vincristine—colon cancer	0.000712	0.00335	CcSEcCtD
Amsacrine—Hypoaesthesia—Fluorouracil—colon cancer	0.000712	0.00335	CcSEcCtD
Amsacrine—Angiopathy—Vincristine—colon cancer	0.000696	0.00327	CcSEcCtD
Amsacrine—Aplastic anaemia—Methotrexate—colon cancer	0.000696	0.00327	CcSEcCtD
Amsacrine—Cardiac disorder—Irinotecan—colon cancer	0.000693	0.00326	CcSEcCtD
Amsacrine—NCOA3—Androgen receptor signaling pathway—EP300—colon cancer	0.000693	0.00801	CbGpPWpGaD
Amsacrine—Mediastinal disorder—Vincristine—colon cancer	0.000691	0.00325	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—DCC—colon cancer	0.00069	0.00797	CbGpPWpGaD
Amsacrine—Mood swings—Capecitabine—colon cancer	0.000685	0.00322	CcSEcCtD
Amsacrine—Alopecia—Vincristine—colon cancer	0.000678	0.00319	CcSEcCtD
Amsacrine—Angiopathy—Irinotecan—colon cancer	0.000678	0.00319	CcSEcCtD
Amsacrine—Blood creatinine increased—Capecitabine—colon cancer	0.000677	0.00319	CcSEcCtD
Amsacrine—NCOA3—Transcriptional regulation of white adipocyte differentiation—TGFB1—colon cancer	0.000676	0.00782	CbGpPWpGaD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—BRAF—colon cancer	0.000676	0.00781	CbGpPWpGaD
Amsacrine—NCOA3—Androgen receptor signaling pathway—SRC—colon cancer	0.000674	0.00779	CbGpPWpGaD
Amsacrine—Mediastinal disorder—Irinotecan—colon cancer	0.000673	0.00317	CcSEcCtD
Amsacrine—Mental disorder—Vincristine—colon cancer	0.000672	0.00316	CcSEcCtD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—TYMS—colon cancer	0.000668	0.00771	CbGpPWpGaD
Amsacrine—Arrhythmia—Irinotecan—colon cancer	0.000667	0.00314	CcSEcCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—CDH1—colon cancer	0.000662	0.00765	CbGpPWpGaD
Amsacrine—Alopecia—Irinotecan—colon cancer	0.00066	0.00311	CcSEcCtD
Amsacrine—Aspartate aminotransferase increased—Capecitabine—colon cancer	0.000651	0.00306	CcSEcCtD
Amsacrine—Sepsis—Methotrexate—colon cancer	0.000643	0.00303	CcSEcCtD
Amsacrine—Arrhythmia—Fluorouracil—colon cancer	0.000639	0.00301	CcSEcCtD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—BRAF—colon cancer	0.000639	0.00738	CbGpPWpGaD
Amsacrine—Alopecia—Fluorouracil—colon cancer	0.000632	0.00297	CcSEcCtD
Amsacrine—Dysphagia—Capecitabine—colon cancer	0.000625	0.00294	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—HNF4A—colon cancer	0.000619	0.00715	CbGpPWpGaD
Amsacrine—CYP2D6—digestive system—colon cancer	0.000618	0.016	CbGeAlD
Amsacrine—Anaemia—Vincristine—colon cancer	0.000617	0.0029	CcSEcCtD
Amsacrine—TOP2A—Gastric Cancer Network 2—MYC—colon cancer	0.000616	0.00711	CbGpPWpGaD
Amsacrine—NCOA3—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—colon cancer	0.000603	0.00697	CbGpPWpGaD
Amsacrine—TOP2A—Gastric Cancer Network 2—EGFR—colon cancer	0.000602	0.00696	CbGpPWpGaD
Amsacrine—Anaemia—Irinotecan—colon cancer	0.000601	0.00283	CcSEcCtD
Amsacrine—Hepatic failure—Methotrexate—colon cancer	0.000599	0.00282	CcSEcCtD
Amsacrine—Leukopenia—Vincristine—colon cancer	0.000598	0.00281	CcSEcCtD
Amsacrine—Pancytopenia—Capecitabine—colon cancer	0.000593	0.00279	CcSEcCtD
Amsacrine—NCOA3—Androgen receptor signaling pathway—EGFR—colon cancer	0.000591	0.00683	CbGpPWpGaD
Amsacrine—Vision blurred—Fluorouracil—colon cancer	0.000587	0.00276	CcSEcCtD
Amsacrine—NCOA3—PPARA activates gene expression—EP300—colon cancer	0.000585	0.00676	CbGpPWpGaD
Amsacrine—ABCB1—epithelium—colon cancer	0.000584	0.0151	CbGeAlD
Amsacrine—Leukopenia—Irinotecan—colon cancer	0.000582	0.00274	CcSEcCtD
Amsacrine—NCOA3—Metabolism—ODC1—colon cancer	0.000582	0.00672	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—CHST5—colon cancer	0.000582	0.00672	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—HNF4A—colon cancer	0.000581	0.00671	CbGpPWpGaD
Amsacrine—KCNH2—lymph node—colon cancer	0.000579	0.015	CbGeAlD
Amsacrine—Convulsion—Vincristine—colon cancer	0.000579	0.00272	CcSEcCtD
Amsacrine—Anaemia—Fluorouracil—colon cancer	0.000576	0.00271	CcSEcCtD
Amsacrine—NCOA3—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—colon cancer	0.000573	0.00662	CbGpPWpGaD
Amsacrine—Weight increased—Capecitabine—colon cancer	0.000568	0.00267	CcSEcCtD
Amsacrine—Weight decreased—Capecitabine—colon cancer	0.000565	0.00266	CcSEcCtD
Amsacrine—Leukopenia—Fluorouracil—colon cancer	0.000558	0.00262	CcSEcCtD
Amsacrine—Infestation NOS—Capecitabine—colon cancer	0.000557	0.00262	CcSEcCtD
Amsacrine—Infestation—Capecitabine—colon cancer	0.000557	0.00262	CcSEcCtD
Amsacrine—Lethargy—Methotrexate—colon cancer	0.000549	0.00258	CcSEcCtD
Amsacrine—Renal failure—Capecitabine—colon cancer	0.000547	0.00258	CcSEcCtD
Amsacrine—Stomatitis—Capecitabine—colon cancer	0.000543	0.00255	CcSEcCtD
Amsacrine—Jaundice—Capecitabine—colon cancer	0.000543	0.00255	CcSEcCtD
Amsacrine—ABCB1—renal system—colon cancer	0.000542	0.014	CbGeAlD
Amsacrine—Infection—Vincristine—colon cancer	0.000541	0.00255	CcSEcCtD
Amsacrine—Convulsion—Fluorouracil—colon cancer	0.00054	0.00254	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle—MLH3—colon cancer	0.000537	0.0062	CbGpPWpGaD
Amsacrine—Confusional state—Irinotecan—colon cancer	0.000535	0.00252	CcSEcCtD
Amsacrine—Thrombocytopenia—Vincristine—colon cancer	0.000534	0.00251	CcSEcCtD
Amsacrine—Haematuria—Capecitabine—colon cancer	0.000531	0.0025	CcSEcCtD
Amsacrine—Infection—Irinotecan—colon cancer	0.000527	0.00248	CcSEcCtD
Amsacrine—Hepatobiliary disease—Capecitabine—colon cancer	0.000527	0.00248	CcSEcCtD
Amsacrine—Agranulocytosis—Capecitabine—colon cancer	0.00052	0.00245	CcSEcCtD
Amsacrine—Thrombocytopenia—Irinotecan—colon cancer	0.00052	0.00244	CcSEcCtD
Amsacrine—Anorexia—Vincristine—colon cancer	0.000519	0.00244	CcSEcCtD
Amsacrine—Confusional state—Fluorouracil—colon cancer	0.000513	0.00241	CcSEcCtD
Amsacrine—Mood swings—Methotrexate—colon cancer	0.00051	0.0024	CcSEcCtD
Amsacrine—Hypotension—Vincristine—colon cancer	0.000509	0.0024	CcSEcCtD
Amsacrine—Bradycardia—Capecitabine—colon cancer	0.000509	0.00239	CcSEcCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—CASP3—colon cancer	0.000507	0.00586	CbGpPWpGaD
Amsacrine—Anorexia—Irinotecan—colon cancer	0.000506	0.00238	CcSEcCtD
Amsacrine—TOP2A—Gastric Cancer Network 2—TP53—colon cancer	0.000506	0.00584	CbGpPWpGaD
Amsacrine—Infection—Fluorouracil—colon cancer	0.000505	0.00238	CcSEcCtD
Amsacrine—Haemoglobin—Capecitabine—colon cancer	0.000503	0.00236	CcSEcCtD
Amsacrine—Hepatitis—Capecitabine—colon cancer	0.0005	0.00235	CcSEcCtD
Amsacrine—Haemorrhage—Capecitabine—colon cancer	0.0005	0.00235	CcSEcCtD
Amsacrine—Thrombocytopenia—Fluorouracil—colon cancer	0.000498	0.00234	CcSEcCtD
Amsacrine—Hypoaesthesia—Capecitabine—colon cancer	0.000497	0.00234	CcSEcCtD
Amsacrine—Tachycardia—Fluorouracil—colon cancer	0.000496	0.00233	CcSEcCtD
Amsacrine—Hypotension—Irinotecan—colon cancer	0.000496	0.00233	CcSEcCtD
Amsacrine—Urinary tract disorder—Capecitabine—colon cancer	0.000494	0.00232	CcSEcCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—CCND1—colon cancer	0.000493	0.0057	CbGpPWpGaD
Amsacrine—Connective tissue disorder—Capecitabine—colon cancer	0.000491	0.00231	CcSEcCtD
Amsacrine—Urethral disorder—Capecitabine—colon cancer	0.00049	0.00231	CcSEcCtD
Amsacrine—Paraesthesia—Vincristine—colon cancer	0.000489	0.0023	CcSEcCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—CTNNB1—colon cancer	0.000488	0.00564	CbGpPWpGaD
Amsacrine—Anorexia—Fluorouracil—colon cancer	0.000485	0.00228	CcSEcCtD
Amsacrine—Paraesthesia—Irinotecan—colon cancer	0.000477	0.00224	CcSEcCtD
Amsacrine—Hypotension—Fluorouracil—colon cancer	0.000475	0.00223	CcSEcCtD
Amsacrine—Decreased appetite—Vincristine—colon cancer	0.000474	0.00223	CcSEcCtD
Amsacrine—Dyspnoea—Irinotecan—colon cancer	0.000473	0.00223	CcSEcCtD
Amsacrine—Gastrointestinal disorder—Vincristine—colon cancer	0.000471	0.00221	CcSEcCtD
Amsacrine—Fatigue—Vincristine—colon cancer	0.00047	0.00221	CcSEcCtD
Amsacrine—TOP2A—Mitotic G1-G1/S phases—TYMS—colon cancer	0.00047	0.00543	CbGpPWpGaD
Amsacrine—Pain—Vincristine—colon cancer	0.000466	0.00219	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	0.000464	0.00536	CbGpPWpGaD
Amsacrine—Cardiac disorder—Capecitabine—colon cancer	0.000464	0.00218	CcSEcCtD
Amsacrine—Decreased appetite—Irinotecan—colon cancer	0.000461	0.00217	CcSEcCtD
Amsacrine—CYP2D6—liver—colon cancer	0.000461	0.0119	CbGeAlD
Amsacrine—Gastrointestinal disorder—Irinotecan—colon cancer	0.000458	0.00216	CcSEcCtD
Amsacrine—TOP2A—Vinorelbine—Vincristine—colon cancer	0.000458	0.0462	CbGdCrCtD
Amsacrine—Fatigue—Irinotecan—colon cancer	0.000458	0.00215	CcSEcCtD
Amsacrine—Paraesthesia—Fluorouracil—colon cancer	0.000456	0.00215	CcSEcCtD
Amsacrine—CYP2D6—Metapathway biotransformation—CHST5—colon cancer	0.000456	0.00527	CbGpPWpGaD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—EP300—colon cancer	0.000454	0.00525	CbGpPWpGaD
Amsacrine—Pain—Irinotecan—colon cancer	0.000454	0.00214	CcSEcCtD
Amsacrine—Angiopathy—Capecitabine—colon cancer	0.000454	0.00213	CcSEcCtD
Amsacrine—Dyspnoea—Fluorouracil—colon cancer	0.000453	0.00213	CcSEcCtD
Amsacrine—Mediastinal disorder—Capecitabine—colon cancer	0.000451	0.00212	CcSEcCtD
Amsacrine—ABCB1—lymphoid tissue—colon cancer	0.00045	0.0117	CbGeAlD
Amsacrine—ABCB1—HIF-1-alpha transcription factor network—HNF4A—colon cancer	0.000447	0.00517	CbGpPWpGaD
Amsacrine—Arrhythmia—Capecitabine—colon cancer	0.000447	0.0021	CcSEcCtD
Amsacrine—Gastrointestinal pain—Vincristine—colon cancer	0.000446	0.0021	CcSEcCtD
Amsacrine—ABCB1—digestive system—colon cancer	0.000445	0.0115	CbGeAlD
Amsacrine—Decreased appetite—Fluorouracil—colon cancer	0.000442	0.00208	CcSEcCtD
Amsacrine—Alopecia—Capecitabine—colon cancer	0.000442	0.00208	CcSEcCtD
Amsacrine—Pancytopenia—Methotrexate—colon cancer	0.000442	0.00208	CcSEcCtD
Amsacrine—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000439	0.00206	CcSEcCtD
Amsacrine—Mental disorder—Capecitabine—colon cancer	0.000438	0.00206	CcSEcCtD
Amsacrine—Feeling abnormal—Irinotecan—colon cancer	0.000437	0.00206	CcSEcCtD
Amsacrine—Malnutrition—Capecitabine—colon cancer	0.000435	0.00205	CcSEcCtD
Amsacrine—Pain—Fluorouracil—colon cancer	0.000435	0.00205	CcSEcCtD
Amsacrine—Gastrointestinal pain—Irinotecan—colon cancer	0.000434	0.00204	CcSEcCtD
Amsacrine—Abdominal pain—Vincristine—colon cancer	0.000431	0.00203	CcSEcCtD
Amsacrine—Body temperature increased—Vincristine—colon cancer	0.000431	0.00203	CcSEcCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—VEGFA—colon cancer	0.00043	0.00497	CbGpPWpGaD
Amsacrine—Abdominal pain—Irinotecan—colon cancer	0.00042	0.00197	CcSEcCtD
Amsacrine—Body temperature increased—Irinotecan—colon cancer	0.00042	0.00197	CcSEcCtD
Amsacrine—Feeling abnormal—Fluorouracil—colon cancer	0.000419	0.00197	CcSEcCtD
Amsacrine—NCOA3—Androgen receptor signaling pathway—AKT1—colon cancer	0.000419	0.00484	CbGpPWpGaD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—SRC—colon cancer	0.000417	0.00482	CbGpPWpGaD
Amsacrine—Infestation—Methotrexate—colon cancer	0.000415	0.00195	CcSEcCtD
Amsacrine—Infestation NOS—Methotrexate—colon cancer	0.000415	0.00195	CcSEcCtD
Amsacrine—Vision blurred—Capecitabine—colon cancer	0.00041	0.00193	CcSEcCtD
Amsacrine—ABCB1—bone marrow—colon cancer	0.00041	0.0106	CbGeAlD
Amsacrine—Renal failure—Methotrexate—colon cancer	0.000408	0.00192	CcSEcCtD
Amsacrine—Stomatitis—Methotrexate—colon cancer	0.000404	0.0019	CcSEcCtD
Amsacrine—Urticaria—Fluorouracil—colon cancer	0.000404	0.0019	CcSEcCtD
Amsacrine—Anaemia—Capecitabine—colon cancer	0.000402	0.00189	CcSEcCtD
Amsacrine—Body temperature increased—Fluorouracil—colon cancer	0.000402	0.00189	CcSEcCtD
Amsacrine—Hypersensitivity—Vincristine—colon cancer	0.000402	0.00189	CcSEcCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—MYC—colon cancer	0.000396	0.00457	CbGpPWpGaD
Amsacrine—Haematuria—Methotrexate—colon cancer	0.000395	0.00186	CcSEcCtD
Amsacrine—NCOA3—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—colon cancer	0.000395	0.00456	CbGpPWpGaD
Amsacrine—ABCB1—vagina—colon cancer	0.000393	0.0102	CbGeAlD
Amsacrine—Hepatobiliary disease—Methotrexate—colon cancer	0.000392	0.00184	CcSEcCtD
Amsacrine—Hypersensitivity—Irinotecan—colon cancer	0.000391	0.00184	CcSEcCtD
Amsacrine—Asthenia—Vincristine—colon cancer	0.000391	0.00184	CcSEcCtD
Amsacrine—Leukopenia—Capecitabine—colon cancer	0.00039	0.00183	CcSEcCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—EGFR—colon cancer	0.000387	0.00447	CbGpPWpGaD
Amsacrine—Agranulocytosis—Methotrexate—colon cancer	0.000387	0.00182	CcSEcCtD
Amsacrine—Asthenia—Irinotecan—colon cancer	0.000381	0.00179	CcSEcCtD
Amsacrine—Hypersensitivity—Fluorouracil—colon cancer	0.000375	0.00176	CcSEcCtD
Amsacrine—Haemoglobin—Methotrexate—colon cancer	0.000374	0.00176	CcSEcCtD
Amsacrine—Diarrhoea—Vincristine—colon cancer	0.000373	0.00175	CcSEcCtD
Amsacrine—Haemorrhage—Methotrexate—colon cancer	0.000372	0.00175	CcSEcCtD
Amsacrine—Hepatitis—Methotrexate—colon cancer	0.000372	0.00175	CcSEcCtD
Amsacrine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000368	0.00173	CcSEcCtD
Amsacrine—Urinary tract disorder—Methotrexate—colon cancer	0.000368	0.00173	CcSEcCtD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—EGFR—colon cancer	0.000366	0.00423	CbGpPWpGaD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—KRAS—colon cancer	0.000366	0.00422	CbGpPWpGaD
Amsacrine—Urethral disorder—Methotrexate—colon cancer	0.000365	0.00172	CcSEcCtD
Amsacrine—Diarrhoea—Irinotecan—colon cancer	0.000363	0.00171	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—ABCB1—colon cancer	0.000362	0.00419	CbGpPWpGaD
Amsacrine—Dizziness—Vincristine—colon cancer	0.00036	0.0017	CcSEcCtD
Amsacrine—Confusional state—Capecitabine—colon cancer	0.000358	0.00169	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	0.000356	0.00411	CbGpPWpGaD
Amsacrine—Infection—Capecitabine—colon cancer	0.000353	0.00166	CcSEcCtD
Amsacrine—Dizziness—Irinotecan—colon cancer	0.000351	0.00165	CcSEcCtD
Amsacrine—Diarrhoea—Fluorouracil—colon cancer	0.000348	0.00164	CcSEcCtD
Amsacrine—Thrombocytopenia—Capecitabine—colon cancer	0.000348	0.00164	CcSEcCtD
Amsacrine—Tachycardia—Capecitabine—colon cancer	0.000347	0.00163	CcSEcCtD
Amsacrine—Vomiting—Vincristine—colon cancer	0.000347	0.00163	CcSEcCtD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—KRAS—colon cancer	0.000346	0.00399	CbGpPWpGaD
Amsacrine—Cardiac disorder—Methotrexate—colon cancer	0.000345	0.00163	CcSEcCtD
Amsacrine—Skin disorder—Capecitabine—colon cancer	0.000345	0.00162	CcSEcCtD
Amsacrine—Rash—Vincristine—colon cancer	0.000344	0.00162	CcSEcCtD
Amsacrine—Dermatitis—Vincristine—colon cancer	0.000343	0.00162	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	0.000343	0.00396	CbGpPWpGaD
Amsacrine—TOP2A—Circadian rythm related genes—TYMS—colon cancer	0.000342	0.00395	CbGpPWpGaD
Amsacrine—Headache—Vincristine—colon cancer	0.000341	0.00161	CcSEcCtD
Amsacrine—Anorexia—Capecitabine—colon cancer	0.000339	0.00159	CcSEcCtD
Amsacrine—Angiopathy—Methotrexate—colon cancer	0.000338	0.00159	CcSEcCtD
Amsacrine—Vomiting—Irinotecan—colon cancer	0.000337	0.00159	CcSEcCtD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—CCND1—colon cancer	0.000336	0.00388	CbGpPWpGaD
Amsacrine—Dizziness—Fluorouracil—colon cancer	0.000336	0.00158	CcSEcCtD
Amsacrine—Mediastinal disorder—Methotrexate—colon cancer	0.000335	0.00158	CcSEcCtD
Amsacrine—Rash—Irinotecan—colon cancer	0.000335	0.00157	CcSEcCtD
Amsacrine—Dermatitis—Irinotecan—colon cancer	0.000334	0.00157	CcSEcCtD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—colon cancer	0.000333	0.00385	CbGpPWpGaD
Amsacrine—Headache—Irinotecan—colon cancer	0.000332	0.00156	CcSEcCtD
Amsacrine—Hypotension—Capecitabine—colon cancer	0.000332	0.00156	CcSEcCtD
Amsacrine—ABCB1—liver—colon cancer	0.000331	0.00858	CbGeAlD
Amsacrine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.00033	0.00382	CbGpPWpGaD
Amsacrine—Alopecia—Methotrexate—colon cancer	0.000329	0.00155	CcSEcCtD
Amsacrine—Mental disorder—Methotrexate—colon cancer	0.000326	0.00153	CcSEcCtD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1A—colon cancer	0.000325	0.00376	CbGpPWpGaD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—TP53—colon cancer	0.000325	0.00375	CbGpPWpGaD
Amsacrine—Malnutrition—Methotrexate—colon cancer	0.000324	0.00152	CcSEcCtD
Amsacrine—Nausea—Vincristine—colon cancer	0.000324	0.00152	CcSEcCtD
Amsacrine—Vomiting—Fluorouracil—colon cancer	0.000323	0.00152	CcSEcCtD
Amsacrine—Rash—Fluorouracil—colon cancer	0.000321	0.00151	CcSEcCtD
Amsacrine—Dermatitis—Fluorouracil—colon cancer	0.00032	0.00151	CcSEcCtD
Amsacrine—Paraesthesia—Capecitabine—colon cancer	0.000319	0.0015	CcSEcCtD
Amsacrine—Headache—Fluorouracil—colon cancer	0.000318	0.0015	CcSEcCtD
Amsacrine—Dyspnoea—Capecitabine—colon cancer	0.000317	0.00149	CcSEcCtD
Amsacrine—Nausea—Irinotecan—colon cancer	0.000315	0.00148	CcSEcCtD
Amsacrine—TOP2A—Vinblastine—Vincristine—colon cancer	0.000315	0.0318	CbGdCrCtD
Amsacrine—Decreased appetite—Capecitabine—colon cancer	0.000309	0.00145	CcSEcCtD
Amsacrine—Gastrointestinal disorder—Capecitabine—colon cancer	0.000307	0.00144	CcSEcCtD
Amsacrine—Fatigue—Capecitabine—colon cancer	0.000306	0.00144	CcSEcCtD
Amsacrine—Vision blurred—Methotrexate—colon cancer	0.000305	0.00144	CcSEcCtD
Amsacrine—Pain—Capecitabine—colon cancer	0.000304	0.00143	CcSEcCtD
Amsacrine—Nausea—Fluorouracil—colon cancer	0.000302	0.00142	CcSEcCtD
Amsacrine—Anaemia—Methotrexate—colon cancer	0.000299	0.00141	CcSEcCtD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—HRAS—colon cancer	0.000294	0.00339	CbGpPWpGaD
Amsacrine—Feeling abnormal—Capecitabine—colon cancer	0.000293	0.00138	CcSEcCtD
Amsacrine—Gastrointestinal pain—Capecitabine—colon cancer	0.00029	0.00137	CcSEcCtD
Amsacrine—Leukopenia—Methotrexate—colon cancer	0.00029	0.00136	CcSEcCtD
Amsacrine—Urticaria—Capecitabine—colon cancer	0.000282	0.00133	CcSEcCtD
Amsacrine—Abdominal pain—Capecitabine—colon cancer	0.000281	0.00132	CcSEcCtD
Amsacrine—Body temperature increased—Capecitabine—colon cancer	0.000281	0.00132	CcSEcCtD
Amsacrine—Convulsion—Methotrexate—colon cancer	0.000281	0.00132	CcSEcCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—AKT1—colon cancer	0.000274	0.00317	CbGpPWpGaD
Amsacrine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000274	0.00129	CcSEcCtD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—MYC—colon cancer	0.00027	0.00312	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—PPARG—colon cancer	0.000269	0.00311	CbGpPWpGaD
Amsacrine—Confusional state—Methotrexate—colon cancer	0.000267	0.00125	CcSEcCtD
Amsacrine—Infection—Methotrexate—colon cancer	0.000263	0.00124	CcSEcCtD
Amsacrine—Hypersensitivity—Capecitabine—colon cancer	0.000262	0.00123	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—APC—colon cancer	0.000261	0.00302	CbGpPWpGaD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—AKT1—colon cancer	0.000259	0.003	CbGpPWpGaD
Amsacrine—Thrombocytopenia—Methotrexate—colon cancer	0.000259	0.00122	CcSEcCtD
Amsacrine—Skin disorder—Methotrexate—colon cancer	0.000257	0.00121	CcSEcCtD
Amsacrine—Asthenia—Capecitabine—colon cancer	0.000255	0.0012	CcSEcCtD
Amsacrine—ABCB1—lymph node—colon cancer	0.000254	0.00658	CbGeAlD
Amsacrine—Anorexia—Methotrexate—colon cancer	0.000252	0.00119	CcSEcCtD
Amsacrine—Hypotension—Methotrexate—colon cancer	0.000247	0.00116	CcSEcCtD
Amsacrine—Diarrhoea—Capecitabine—colon cancer	0.000243	0.00114	CcSEcCtD
Amsacrine—TOP2A—Circadian rythm related genes—PPARG—colon cancer	0.000242	0.0028	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—PPARG—colon cancer	0.00024	0.00277	CbGpPWpGaD
Amsacrine—Paraesthesia—Methotrexate—colon cancer	0.000237	0.00112	CcSEcCtD
Amsacrine—TOP2A—Mitotic G1-G1/S phases—CCND1—colon cancer	0.000237	0.00273	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—MLH1—colon cancer	0.000236	0.00273	CbGpPWpGaD
Amsacrine—Dyspnoea—Methotrexate—colon cancer	0.000236	0.00111	CcSEcCtD
Amsacrine—Dizziness—Capecitabine—colon cancer	0.000235	0.00111	CcSEcCtD
Amsacrine—Decreased appetite—Methotrexate—colon cancer	0.00023	0.00108	CcSEcCtD
Amsacrine—TOP2A—Mitotic G1-G1/S phases—CDKN1A—colon cancer	0.000229	0.00264	CbGpPWpGaD
Amsacrine—Gastrointestinal disorder—Methotrexate—colon cancer	0.000228	0.00107	CcSEcCtD
Amsacrine—Fatigue—Methotrexate—colon cancer	0.000228	0.00107	CcSEcCtD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—DCC—colon cancer	0.000227	0.00262	CbGpPWpGaD
Amsacrine—Pain—Methotrexate—colon cancer	0.000226	0.00106	CcSEcCtD
Amsacrine—Vomiting—Capecitabine—colon cancer	0.000226	0.00106	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle, Mitotic—BUB1B—colon cancer	0.000225	0.0026	CbGpPWpGaD
Amsacrine—Rash—Capecitabine—colon cancer	0.000224	0.00105	CcSEcCtD
Amsacrine—Dermatitis—Capecitabine—colon cancer	0.000224	0.00105	CcSEcCtD
Amsacrine—Headache—Capecitabine—colon cancer	0.000223	0.00105	CcSEcCtD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—TP53—colon cancer	0.000221	0.00256	CbGpPWpGaD
Amsacrine—Feeling abnormal—Methotrexate—colon cancer	0.000218	0.00103	CcSEcCtD
Amsacrine—Gastrointestinal pain—Methotrexate—colon cancer	0.000216	0.00102	CcSEcCtD
Amsacrine—Nausea—Capecitabine—colon cancer	0.000211	0.000993	CcSEcCtD
Amsacrine—Urticaria—Methotrexate—colon cancer	0.00021	0.000988	CcSEcCtD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—CASP3—colon cancer	0.000209	0.00242	CbGpPWpGaD
Amsacrine—Body temperature increased—Methotrexate—colon cancer	0.000209	0.000984	CcSEcCtD
Amsacrine—Abdominal pain—Methotrexate—colon cancer	0.000209	0.000984	CcSEcCtD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—CTNNB1—colon cancer	0.000202	0.00233	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—BUB1B—colon cancer	0.000201	0.00232	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	0.000198	0.00229	CbGpPWpGaD
Amsacrine—Hypersensitivity—Methotrexate—colon cancer	0.000195	0.000917	CcSEcCtD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—HNF4A—colon cancer	0.000191	0.00221	CbGpPWpGaD
Amsacrine—TOP2A—Mitotic G1-G1/S phases—MYC—colon cancer	0.00019	0.00219	CbGpPWpGaD
Amsacrine—Asthenia—Methotrexate—colon cancer	0.00019	0.000893	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—CTNNB1—colon cancer	0.000189	0.00219	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	0.000189	0.00218	CbGpPWpGaD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—EP300—colon cancer	0.000187	0.00216	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	0.000184	0.00213	CbGpPWpGaD
Amsacrine—Diarrhoea—Methotrexate—colon cancer	0.000181	0.000851	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	0.000179	0.00207	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	0.000177	0.00205	CbGpPWpGaD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—VEGFA—colon cancer	0.000177	0.00205	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—EP300—colon cancer	0.000176	0.00203	CbGpPWpGaD
Amsacrine—KCNH2—Neuronal System—BRAF—colon cancer	0.000175	0.00202	CbGpPWpGaD
Amsacrine—Dizziness—Methotrexate—colon cancer	0.000175	0.000823	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	0.000173	0.002	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—TYMS—colon cancer	0.000172	0.00199	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—SRC—colon cancer	0.000171	0.00198	CbGpPWpGaD
Amsacrine—Vomiting—Methotrexate—colon cancer	0.000168	0.000791	CcSEcCtD
Amsacrine—Rash—Methotrexate—colon cancer	0.000167	0.000784	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—VEGFA—colon cancer	0.000167	0.00193	CbGpPWpGaD
Amsacrine—Dermatitis—Methotrexate—colon cancer	0.000167	0.000784	CcSEcCtD
Amsacrine—Headache—Methotrexate—colon cancer	0.000166	0.000779	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	0.000165	0.00191	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—NRAS—colon cancer	0.000165	0.0019	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	0.00016	0.00185	CbGpPWpGaD
Amsacrine—TOP2A—Circadian rythm related genes—EP300—colon cancer	0.000158	0.00183	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—EP300—colon cancer	0.000157	0.00182	CbGpPWpGaD
Amsacrine—Nausea—Methotrexate—colon cancer	0.000157	0.000739	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	0.000156	0.00181	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—TYMS—colon cancer	0.000154	0.00178	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—ABCB1—colon cancer	0.000154	0.00178	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—TGFB1—colon cancer	0.000153	0.00177	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	0.000153	0.00177	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—TYMS—colon cancer	0.000151	0.00174	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—EGFR—colon cancer	0.00015	0.00173	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	0.000144	0.00166	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	0.000143	0.00166	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—KRAS—colon cancer	0.000142	0.00164	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	0.000141	0.00162	CbGpPWpGaD
Amsacrine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—colon cancer	0.000141	0.00162	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—CA7—colon cancer	0.000139	0.0016	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	0.000133	0.00153	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—CA7—colon cancer	0.000131	0.00151	CbGpPWpGaD
Amsacrine—ABCB1—HIF-1-alpha transcription factor network—EP300—colon cancer	0.000127	0.00147	CbGpPWpGaD
Amsacrine—ABCB1—Allograft Rejection—CASP3—colon cancer	0.000123	0.00142	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	0.000122	0.00141	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—HRAS—colon cancer	0.00012	0.00139	CbGpPWpGaD
Amsacrine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—colon cancer	0.00012	0.00139	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	0.000118	0.00136	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	0.000117	0.00135	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	0.000116	0.00134	CbGpPWpGaD
Amsacrine—TOP2A—Circadian rythm related genes—TP53—colon cancer	0.000113	0.00131	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	0.000113	0.0013	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—PPARG—colon cancer	0.000107	0.00124	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—AKT1—colon cancer	0.000106	0.00123	CbGpPWpGaD
Amsacrine—ABCB1—Allograft Rejection—VEGFA—colon cancer	0.000104	0.0012	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	9.97e-05	0.00115	CbGpPWpGaD
Amsacrine—ABCB1—Allograft Rejection—TGFB1—colon cancer	9.57e-05	0.00111	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—CCND1—colon cancer	8.68e-05	0.001	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—APC—colon cancer	8.6e-05	0.000994	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—PTGS2—colon cancer	8.41e-05	0.000972	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—ODC1—colon cancer	8.4e-05	0.00097	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—CHST5—colon cancer	8.4e-05	0.00097	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—CDKN1A—colon cancer	8.39e-05	0.00097	CbGpPWpGaD
Amsacrine—KCNH2—Neuronal System—HRAS—colon cancer	8.05e-05	0.00093	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—EP300—colon cancer	7.99e-05	0.000923	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—CHST5—colon cancer	7.91e-05	0.000914	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—ODC1—colon cancer	7.91e-05	0.000914	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—CCND1—colon cancer	7.76e-05	0.000896	CbGpPWpGaD
Amsacrine—ABCB1—HIF-1-alpha transcription factor network—AKT1—colon cancer	7.68e-05	0.000887	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—CDKN1A—colon cancer	7.5e-05	0.000867	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—EP300—colon cancer	7.14e-05	0.000825	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—EP300—colon cancer	7e-05	0.000808	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—MYC—colon cancer	6.96e-05	0.000804	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	6.53e-05	0.000755	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—MYC—colon cancer	6.22e-05	0.000719	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	6.06e-05	0.0007	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	5.9e-05	0.000682	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	5.84e-05	0.000675	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	5.71e-05	0.00066	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	5.43e-05	0.000628	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	5.28e-05	0.00061	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—PIK3CA—colon cancer	5.18e-05	0.000598	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	5.14e-05	0.000594	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—TP53—colon cancer	5.11e-05	0.00059	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	4.73e-05	0.000547	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	4.72e-05	0.000546	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	4.63e-05	0.000535	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	4.37e-05	0.000505	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—AKT1—colon cancer	4.23e-05	0.000489	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	4.02e-05	0.000464	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	3.89e-05	0.000449	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	3.28e-05	0.000379	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—TYMS—colon cancer	2.18e-05	0.000252	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—ABCB1—colon cancer	2.09e-05	0.000242	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—TYMS—colon cancer	2.05e-05	0.000237	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—PPARG—colon cancer	1.54e-05	0.000178	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—PPARG—colon cancer	1.45e-05	0.000168	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—PTGS2—colon cancer	1.21e-05	0.00014	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—PTGS2—colon cancer	1.14e-05	0.000132	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—EP300—colon cancer	1.01e-05	0.000117	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—EP300—colon cancer	9.52e-06	0.00011	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—PIK3CA—colon cancer	7.47e-06	8.63e-05	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—PIK3CA—colon cancer	7.04e-06	8.14e-05	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—AKT1—colon cancer	6.1e-06	7.05e-05	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—AKT1—colon cancer	5.75e-06	6.65e-05	CbGpPWpGaD
